Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03QKW
|
|||
| Former ID |
DIB003626
|
|||
| Drug Name |
KUC-7483
|
|||
| Synonyms |
Ritobegron ethyl ester; KUC-7322; Beta 3 adrenoceptor agonists (urinary incontinence), Kissei; N-phenylglycine derivatives, Kissei; 4-hydroxynorephedrine derivative (urinary incontinence), Kissei
Click to Show/Hide
|
|||
| Indication | Overactive bladder [ICD-11: GC50.0; ICD-10: N32.8] | Phase 1 | [1] | |
| Company |
Kissei Pharmaceutical Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H27NO5
|
|||
| Canonical SMILES |
CC1=CC(=C(C=C1OCC(=O)O)C)CCNC(C)C(C2=CC=C(C=C2)O)O
|
|||
| InChI |
1S/C21H27NO5/c1-13-11-19(27-12-20(24)25)14(2)10-17(13)8-9-22-15(3)21(26)16-4-6-18(23)7-5-16/h4-7,10-11,15,21-23,26H,8-9,12H2,1-3H3,(H,24,25)/t15-,21-/m0/s1
|
|||
| InChIKey |
VMMYRRFPMAGXNP-BTYIYWSLSA-N
|
|||
| CAS Number |
CAS 255734-04-4
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-3 (ADRB3) | Target Info | Agonist | [2], [3] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Salivary secretion | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta3 adrenergic receptor signaling pathway | ||||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02256735) Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers. U.S.National Institutes of Health. | |||
| REF 2 | Effects of ritobegron (KUC-7483), a novel selective beta3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther. 2012 Jul;342(1):163-8. | |||
| REF 3 | Mirabegron for the treatment of overactive bladder. Drugs Today (Barc). 2012 Jan;48(1):25-32. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.